A U.S. District Court in New York has approved the terms of a settlement between Del Global Technologies and its shareholders, dismissing all claims against Del and other defendants without any findings of liability or wrongdoing
A U.S. District Court in New York has approved the terms of a settlement between Del Global Technologies and its shareholders, dismissing all claims against Del and other defendants without any findings of liability or wrongdoing by any party, according to the company. Under the court-approved agreement, members of the class action will receive $2 million in cash and $2 million of subordinated promissory notes due in five years bearing interest at 6% per annum. Class action litigants will also receive 2.5 million shares of Del common stock with warrants to purchase one million shares of Del's common stock exercisable at $2 per share, expiring six years from the date of execution. Del Global develops and markets stationary and portable x-ray systems, as well as radio-frequency, mammography, and dental imaging systems. The company also makes high-voltage power conversion subsystems for medical and industrial applications.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.